映恩生物IPO披露审核问询函回复,融资必要性、无实际控制人等情况遭到追问

北京商报
Yesterday

10月9日,映恩生物(Duality Biotherapeutics, Inc.)科创板IPO对外披露了审核问询函回复。  据悉,映恩生物是一家临床阶段的创新生物药企,为癌症和自身免疫性疾病患者研发新一代抗体偶联药物(ADC)。  映恩生物本次冲击上市,拟募集资金41亿元,全部用于新药研发项目,包括DB-1311及DB-1310的全球研究与开发,以及其他在研产品包括DB-1317、DB-1324及...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10